Pinealon (EDR Peptide)

Classification: Synthetic Tripeptide, Peptide Bioregulator, Neuroprotective Agent Sequence: Glu-Asp-Arg (E-D-R) Molecular Formula: C₁₅H₂₆N₆O₈ Molecular Weight: 418.407 Da Origin: Isolated from bovine pineal gland/cerebral cortex (Khavinson's Russian research) FDA Status: NOT APPROVED - Research Use Only

Executive Summary

Pinealon is an ultrashort synthetic tripeptide (Glu-Asp-Arg, abbreviated EDR) originally isolated from bovine pineal gland and cerebral cortex extracts by Russian researchers at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Dr. Vladimir Khavinson. With a molecular weight of only 418 Da, Pinealon belongs to a class of compounds termed "peptide bioregulators"—substances claimed to interact directly with DNA to modulate gene expression in tissue-specific ways.

Proposed Mechanisms: Pinealon's neuroprotective effects are attributed to: (1) Direct gene regulation via nuclear penetration and binding to DNA regulatory sequences, activating transcription of protective genes (SIRT1, SIRT3, antioxidant enzymes); (2) Antioxidant activity through reduction of reactive oxygen species (ROS) and lipid peroxidation; (3) Anti-apoptotic signaling by suppressing programmed cell death pathways in neurons; (4) MAP kinase modulation by delaying stress-activated kinase cascades; and (5) Dendritic spine preservation in hippocampal neurons, preventing synaptic loss associated with neurodegeneration.

Clinical Evidence: Limited human trials exist, primarily from Russian medical literature. A study of 72 patients with traumatic brain injury (TBI) receiving oral Pinealon (0.2 mg twice daily for 20-30 days) reported improvements in memory, headache reduction, emotional stability, and cognitive performance. Another trial in 75 elderly subjects showed enhanced psycho-emotional and central nervous system function. However, these studies lack Western peer review, randomized placebo controls, and independent replication—mirroring the single-source research pattern seen with other Khavinson bioregulators (e.g., Epitalon, Thymalin).

Pharmacokinetics: Pinealon's small size (~418 Da) and net positive charge (arginine residue) facilitate blood-brain barrier (BBB) penetration and cellular uptake. Oral bioavailability is claimed to be surprisingly high for a peptide due to its ultrashort length, though quantitative data are lacking. Subcutaneous administration provides superior bioavailability in animal models. No published half-life data exist in English-language literature.

Safety Profile: Reported as well-tolerated in limited trials with minimal side effects (mild headaches, nausea, injection site reactions). No serious adverse events documented. However, long-term safety (>1 year), cancer risk, and interactions remain uncharacterized due to absence of Phase 2/3 trials by Western regulatory standards.

Critical Limitations: ALL research on Pinealon originates from a single Russian laboratory (Khavinson's group) with ZERO independent replication by other institutions. The peptide is NOT FDA-approved, marketed only as a "research chemical," and evidence base is insufficient for clinical use outside of experimental settings.

Core Peptides Availability: NOT AVAILABLE (WebFetch returned image data; no product listing found)

Bottom Line: Pinealon is a theoretically intriguing neuroprotective peptide with preliminary evidence suggesting cognitive and neurological benefits in TBI and age-related decline. However, the lack of rigorous, independently replicated clinical trials, FDA approval, and long-term safety data render its therapeutic use speculative and unsuitable for medical recommendation.

Goal Relevance:

• Improve memory and cognitive performance after a brain injury
• Enhance emotional stability and reduce headaches following traumatic brain injury
• Support cognitive function and mental clarity in aging individuals
• Protect brain health and prevent neurodegeneration
• Boost antioxidant defenses to combat oxidative stress in the brain
• Aid in recovery from stress-related cognitive decline

Chemical Structure & Composition

Primary Structure

Amino Acid Sequence: Glu-Asp-Arg (E-D-R)

Structural Representation:

HOOC-CH₂-CH₂-CH(NH₂)-CO-NH-CH(CH₂-COOH)-CO-NH-CH(CH₂-CH₂-CH₂-NH-C(NH₂)=NH)-COOH
  Glutamic Acid        Aspartic Acid              Arginine

Tripeptide Classification:

• Ultrashort peptide: Only 3 amino acids (vs. typical bioactive peptides with 10-50 residues)
• Acidic-Acidic-Basic motif: Two acidic residues (Glu, Asp) followed by one basic residue (Arg)
• Net Charge (pH 7.4): Approximately -1 (two carboxyl groups from Glu/Asp; one guanidinium from Arg partially protonated)

Physicochemical Properties

• Molecular Formula: C₁₅H₂₆N₆O₈
• Molecular Weight: 418.407 Da (some sources cite ~390 Da due to rounding or different ionization states)
• Solubility: Highly water-soluble due to charged residues
• Membrane Permeability: GOOD for a peptide; ultrashort length and amphipathic character facilitate cellular uptake
• BBB Penetration: Enhanced compared to larger peptides; positive charge of arginine may aid transcytosis
• Stability: Susceptible to peptidases (aminopeptidases, carboxypeptidases); acidic residues may confer modest protease resistance

Synthesis & Origin

Natural Source:

• Originally isolated from bovine pineal gland and cerebral cortex extracts
• Identified by Khavinson's laboratory as an active component of polypeptide drug Cortexin (neuroprotective brain extract)

Synthetic Production:

• Commercially produced via solid-phase peptide synthesis (SPPS)
• Fmoc chemistry used to sequentially couple amino acids
• Purified via HPLC; typical purity ≥98%

Synonyms:

• EDR peptide (one-letter amino acid code)
• T-33 peptide
• Glutamylaspartylarginine
• PubChem CID: 18220191

Comparison to Related Bioregulators

References:

• Pinealon Peptide - Peptide Sciences
• Pinealon Wikipedia
• Overview of Pineal Peptides - PMC

Mechanism of Action

1. Direct Gene Expression Modulation (Primary Hypothesis)

Bioregulator Concept:

• Khavinson's central theory: ultrashort peptides (2-4 amino acids) can enter the nucleus and bind to specific DNA sequences, thereby regulating gene transcription in a tissue-specific manner
• Pinealon purportedly targets genes related to neuronal survival, antioxidant defense, and synaptic plasticity

Proposed Mechanism:

1. Cellular Uptake: Pinealon crosses plasma membrane via passive diffusion (small size) or receptor-mediated endocytosis
2. Nuclear Translocation: Peptide enters nucleus (facilitated by nuclear pore complexes; small molecules <40 kDa can diffuse through)
3. DNA Binding: Interacts with regulatory regions (promoters, enhancers) of target genes
4. Transcriptional Activation: Upregulates expression of neuroprotective genes:
   • SIRT1 & SIRT3 (sirtuins: mitochondrial resilience, DNA repair, stress resistance)
   • SOD, catalase, GPx (antioxidant enzymes)
   • BDNF (brain-derived neurotrophic factor: neurogenesis, synaptic plasticity)
   • Bcl-2 family (anti-apoptotic proteins)

Evidence for DNA Interaction:

• Study title: "EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease" (PMC7795577)
• EDR peptide altered gene expression profiles in neuronal cultures
• Mechanism remains speculative; no crystallographic data showing direct DNA-peptide binding

Skepticism:

• Lack of sequence specificity: A 3-amino-acid peptide is unlikely to have high-affinity, sequence-specific DNA binding (typical DNA-binding domains are 50-200 amino acids)
• Alternative explanation: Pinealon may act via cell surface receptors or cytoplasmic signaling rather than direct gene interaction

2. Antioxidant & ROS Suppression

Oxidative Stress in Neurodegeneration:

• Reactive oxygen species (ROS) damage lipids, proteins, and DNA
• Age-related ROS accumulation contributes to Alzheimer's, Parkinson's, and cognitive decline

Pinealon's Antioxidant Effects:

• In Vitro: Dose-dependent reduction of ROS in cerebellar granule cell cultures
• In Vivo (Animal Models): Normalized lipid peroxidation markers (MDA, 4-HNE)
• Enzyme Activation: Enhanced activity of superoxide dismutase (SOD) and catalase

Mechanism:

• Pinealon may upregulate transcription of antioxidant enzyme genes (via Nrf2/ARE pathway or sirtuin activation)
• Direct ROS scavenging unlikely (peptide lacks redox-active groups)

3. Anti-Apoptotic Effects

Apoptosis in Neurodegeneration:

• Neurons undergo programmed cell death in Alzheimer's, TBI, and ischemic injury
• Key pathways: mitochondrial (Bcl-2/Bax balance), death receptor (Fas/TNFR)

Pinealon's Anti-Apoptotic Activity:

• Dendritic Spine Preservation: Prevented loss of dendritic spines in hippocampal neurons exposed to amyloid-beta (Alzheimer's model)
• Caspase Inhibition: Reduced activation of caspase-3 (executioner caspase) in cultured neurons
• Bcl-2 Upregulation: Shifted Bcl-2/Bax ratio toward survival

Clinical Implication:

• May protect neurons during acute injury (TBI, stroke) or chronic degeneration (AD, PD)

4. MAP Kinase Modulation

MAP Kinase Pathways:

• Mitogen-activated protein kinases (ERK, JNK, p38) mediate cellular responses to stress
• Prolonged activation → inflammation, apoptosis
• Brief activation → survival signals

Pinealon's Effect:

• Increased lag phase of MAP kinase activation in cerebellar granule cells
• Delays stress-induced kinase activation, providing neurons time to mount protective responses
• Reduces downstream inflammatory cytokine production (TNF-α, IL-1β)

5. Synaptic Preservation & Cognitive Enhancement

Dendritic Spines:

• Postsynaptic protrusions where excitatory synapses form
• Loss of spines correlates with memory deficits in Alzheimer's and aging

Pinealon's Effect:

• Prevented dendritic spine loss in hippocampal neurons treated with amyloid-beta oligomers
• Mechanism: Stabilizes actin cytoskeleton via RhoA/ROCK pathway modulation (speculative)

Cognitive Outcomes (Clinical Trials):

• Improved memory and learning in TBI patients
• Enhanced working memory in 59.4% of subjects in one trial
• Reduced headache duration/intensity, improved emotional balance

Summary Table: Mechanisms & Effects

References:

• EDR Peptide: Gene Expression Regulation in Alzheimer's - PMC
• Pinealon: Bioregulator Peptide for Neuroprotection - Peptide Sciences
• Pinealon Increases Cell Viability - ResearchGate

Pharmacokinetics

Critical Limitation: Sparse Human PK Data

NO published pharmacokinetic studies in humans provide quantitative data on bioavailability, half-life, volume of distribution, or clearance. Information below is extrapolated from animal studies and general peptide PK principles.

Absorption & Bioavailability

Oral Administration:

• Claimed: Pinealon has "surprisingly high" oral bioavailability for a peptide due to ultrashort length
• Mechanism: May resist GI peptidase degradation better than larger peptides; small size allows paracellular absorption
• Estimate: 5-20% oral bioavailability (speculative; no data)
• Clinical Use: Most human trials used oral dosing (0.2 mg twice daily), suggesting some systemic absorption

Sublingual Administration:

• Marketed for "optimized bioavailability" via buccal mucosa absorption
• Bypasses first-pass hepatic metabolism
• No comparative bioavailability studies vs. oral

Subcutaneous Injection:

• Animal Data: "Excellent subcutaneous bioavailability in mice"
• Bypasses GI degradation; depot effect provides sustained release
• Estimate: 70-90% bioavailability (typical for SC peptides)

Intravenous:

• 100% bioavailability by definition
• Not commonly used clinically

Distribution

Blood-Brain Barrier (BBB) Penetration:

• Key Advantage: Pinealon's small size (~418 Da) and lipophilicity (from hydrophobic side chains) enhance BBB crossing
• Arginine Residue: Positive charge may facilitate adsorptive-mediated transcytosis
• Evidence: Neuroprotective effects in brain-specific models imply CNS penetration
• Estimate: Likely achieves meaningful CNS concentrations (quantitative data absent)

Tissue Selectivity:

• Claimed: "Selective uptake by pineal gland tissue" (tissue-specific bioregulator concept)
• Evidence: Theoretical; no biodistribution studies published
• Likely Reality: Distributes systemically with preferential uptake by highly vascularized organs (brain, liver, kidney)

Metabolism

Enzymatic Degradation:

• Primary route of elimination for peptides
• Aminopeptidases: Cleave N-terminal glutamic acid
• Carboxypeptidases: Cleave C-terminal arginine
• Endopeptidases: May cleave Glu-Asp or Asp-Arg bonds

Metabolic Products:

• Degraded to constituent amino acids (Glu, Asp, Arg)
• Amino acids re-enter metabolic pools (no toxic metabolites)

Half-Life:

• NO published data
• Estimate: Very short (<1 hour) based on typical tripeptide kinetics
• Ultrashort peptides are rapidly cleared unless chemically modified (acetylation, PEGylation)

Excretion

Renal Clearance:

• Low MW (418 Da) < glomerular filtration cutoff (~60 kDa)
• Filtered by kidneys; excreted in urine
• Renal Impairment: May require dose adjustment (theoretical; no data)

Hepatic Clearance:

• First-pass metabolism significant for oral route
• IV/SC routes bypass hepatic extraction

Duration of Biological Effects

Discrepancy:

• Rapid plasma clearance (t½ <1 hour estimated) vs. prolonged biological effects (memory improvement, neuroprotection lasting weeks)

Explanation:

• Epigenetic changes: Gene expression alterations persist beyond peptide clearance
• Downstream signaling cascades: Activated pathways (SIRT1, Nrf2) continue functioning
• Structural neuronal changes: Preserved dendritic spines are stable structures

Clinical Dosing:

• Daily or twice-daily dosing for 20-30 days despite short half-life
• Supports hypothesis of cumulative gene regulatory effects

Comparative PK: Oral vs. SC

References:

• Pinealon Brain & Memory Support - Paragon
• Pinealon Peptide Benefits - Innerbody

Dosing Protocols

CRITICAL DISCLAIMER

Pinealon is NOT FDA-approved. Dosing information is derived from limited Russian clinical trials, animal research, and unverified supplier recommendations. No standardized medical dosing protocols exist.

Clinical Trial Dosing (Human Studies)

Traumatic Brain Injury (TBI) Study (N=72):

• Population: Patients aged 30-74 with cerebral asthenia post-TBI
• Dose: 0.2 mg (200 mcg) oral, twice daily
• Duration: 20-30 days
• Outcomes: Improved memory, reduced headaches, enhanced emotional stability

Elderly Psycho-Emotional Study (N=75):

• Population: Elderly subjects with CNS functional decline
• Dose: One capsule (dose unspecified) twice daily
• Duration: 14 days (2 weeks)
• Outcomes: Improved cognitive and emotional function

Key Observations:

• Oral route predominates in published trials
• Low doses (0.2 mg = 200 mcg) used
• Short courses (2-4 weeks) typical

Subcutaneous Protocols (Anecdotal/Supplier Recommendations)

Conservative Protocol:

• Dose: 100-200 mcg SC once daily
• Duration: 10-20 days
• Frequency: 1-2 cycles per year
• Reconstitution: 20 mg vial + 2 mL bacteriostatic water = 10 mg/mL; inject 10-20 mcL

Moderate Protocol:

• Dose: 300 mcg SC once daily
• Duration: 10 days
• Titration: Start at 100 mcg; increase by 100 mcg every 3 days if tolerated

High-Dose (Not Clinically Validated):

• Dose: 500 mcg SC daily
• Duration: 10-14 days
• Rationale: Extrapolated from animal studies; no human safety data

Oral Protocols

Based on Clinical Trials:

• Dose: 0.2 mg (200 mcg) twice daily with meals
• Duration: 20-30 days
• Formulation: Capsules (typical product: 20 mg per 60-capsule bottle = ~0.33 mg per capsule)

Maintenance (Theoretical):

• Dose: 0.2 mg once daily
• Duration: Continuous or cyclical (e.g., 3 weeks on, 1 week off)

Sublingual (Marketed but Unvalidated)

Claimed Advantages:

• Faster absorption
• Bypasses GI degradation
• "Optimized bioavailability"

Typical Dosing:

• Dose: 200-500 mcg sublingual, hold under tongue 1-2 minutes
• Frequency: Once or twice daily
• Evidence: None; marketing claims only

Special Populations

Traumatic Brain Injury / Stroke:

• Initiate within days to weeks post-injury
• Oral 0.2 mg BID for 20-30 days
• Adjunct to standard rehabilitation

Mild Cognitive Impairment (MCI):

• Oral 0.2 mg BID for 4 weeks
• Monitor cognitive assessments (MoCA, MMSE)

Alzheimer's Disease (Early Stages):

• Theoretical use based on preclinical data
• NO clinical trials in AD patients
• Dose: 0.2-0.4 mg daily (speculative)

Older Adults (>65 years):

• Standard dosing; no dose adjustment based on limited data
• Potential increased benefit due to age-related neurodegeneration

Contraindications (Theoretical):

• Active brain tumor (peptide may support cell proliferation)
• Pregnancy/lactation (no safety data)
• Severe hepatic/renal impairment (altered PK)

Administration Technique (SC Injection)

1. Reconstitution: Add bacteriostatic water to lyophilized powder (e.g., 20 mg vial + 2 mL water = 10 mg/mL stock)
2. Dosing: For 200 mcg dose, withdraw 0.02 mL (20 mcL) using insulin syringe
3. Injection Sites: Abdomen (2 inches from navel), thigh, or upper arm
4. Technique: Pinch skin, insert 28-31 gauge needle at 45-90°, inject slowly
5. Rotate Sites: Daily rotation prevents lipohypertrophy

Monitoring & Response Assessment

Baseline (If Attempting Use):

• Cognitive testing (MoCA, MMSE, or similar)
• Symptom inventory (headache frequency, mood, energy)
• Optional: Advanced biomarkers (BDNF, oxidative stress markers)

Follow-Up (After 4-Week Course):

• Repeat cognitive testing
• Subjective improvement assessment
• Adverse event monitoring

No Routine Labs Required:

• Peptide bioregulators generally do not require blood monitoring
• Liver/kidney function at baseline if using long-term

References:

• Pinealon Dosage Protocol - Peptide Dosages
• Pinealon Benefits & Dosage - Lindy Health

Clinical Research & Evidence

CRITICAL LIMITATION: Single-Source Research

ALL published research on Pinealon originates from Russian institutions, primarily the St. Petersburg Institute of Bioregulation and Gerontology under Dr. Vladimir Khavinson. There has been ZERO independent replication by Western research groups. This pattern mirrors other Khavinson bioregulators (Epitalon, Thymalin) and raises concerns about publication bias, methodological rigor, and reproducibility.

Preclinical Studies

Study 1: ROS Suppression & Cell Viability (In Vitro)

• Model: Cerebellar granule cell cultures
• Intervention: Pinealon at varying concentrations
• Key Findings:
  • Dose-dependent reduction in ROS accumulation
  • Increased cell viability under oxidative stress
  • Delayed MAP kinase activation (protective signaling)
• Significance: Demonstrates antioxidant and neuroprotective mechanisms
• Limitation: In vitro only; no in vivo validation

Study 2: Alzheimer's Model (In Vitro - PMC7795577)

• Title: "EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease"
• Model: Hippocampal neurons exposed to amyloid-beta oligomers
• Intervention: EDR (Pinealon) treatment
• Key Findings:
  • Prevented dendritic spine loss (synaptic preservation)
  • Reduced amyloid-beta toxicity
  • Altered gene expression profiles related to neuroprotection
• Significance: Suggests potential AD therapeutic application
• Limitation: Cell culture model; AD pathology is multifactorial and not fully recapitulated in vitro

Study 3: Animal Models (Rodents)

• Models: Aging rats, ischemic brain injury models
• Intervention: Pinealon SC or oral administration
• Key Findings:
  • Improved cognitive performance in aged rats (Morris water maze, passive avoidance)
  • Reduced infarct size in stroke models
  • Normalized antioxidant enzyme activity (SOD, catalase)
  • Restored circadian rhythms (pineal-specific effect)
• Significance: In vivo confirmation of neuroprotection
• Limitation: Rodent models; uncertain translation to humans

Human Clinical Studies

Study 1: Traumatic Brain Injury (TBI) & Cerebral Asthenia (N=72)

• Design: Open-label, uncontrolled clinical trial
• Population: Patients aged 30-74 with post-TBI cerebral asthenia
• Intervention: Oral Pinealon 0.2 mg twice daily for 20-30 days + standard therapy
• Primary Outcomes:
  • Memory improvement: Subjective and objective measures
  • Headache reduction: Decreased duration and intensity
  • Emotional stability: Improved mood regulation
  • Enhanced performance: Better work/daily function efficacy
• Statistical Significance: Reported as significant vs. baseline; no placebo group
• Limitations:
  • No placebo control (open-label)
  • Small sample size (N=72)
  • Short follow-up (unclear duration post-treatment)
  • Published in Russian literature; limited international peer review
  • Confounded by standard therapy

Study 2: Elderly Psycho-Emotional Function (N=75)

• Design: Uncontrolled trial
• Population: Elderly subjects with CNS functional decline
• Intervention: Pinealon capsules (dose unspecified) twice daily for 2 weeks
• Primary Outcomes:
  • Improved psycho-emotional state
  • Enhanced CNS function (measures unspecified)
• Limitations:
  • No placebo control
  • Vague outcome measures
  • Short duration (2 weeks)
  • Lack of objective cognitive testing

Study 3: Working Memory Trial (N=Unknown, ~59.4% Response Rate)

• Design: Details unclear from available summaries
• Outcome: 59.4% of subjects showed improved working memory
• Limitation: No full publication identified; data from supplier marketing materials

Evidence Gaps

NO Randomized, Double-Blind, Placebo-Controlled Trials (RCTs):

• Gold standard for clinical evidence
• All Pinealon trials are open-label or uncontrolled

NO Trials in Diagnosed Alzheimer's or Parkinson's Patients:

• Despite preclinical AD/PD models, no human trials in these populations

NO Long-Term Safety Trials (>6 Months):

• Unknown effects of chronic use
• Cancer risk unassessed

NO Dose-Response Studies:

• Optimal dosing unknown
• 0.2 mg used empirically without titration studies

NO Western/Independent Replication:

• All research from single Russian group
• No validation by European, American, or Asian institutions

Evidence Quality Assessment

Overall Evidence Grade: INSUFFICIENT for FDA approval or clinical recommendation by Western medical standards.

References:

• EDR Peptide in Alzheimer's Pathogenesis - PMC
• Pinealon Research on Neuroprotection - Core Peptides
• Pinealon Increases Cell Viability - ResearchGate

Safety Profile

Human Safety Data (Limited)

Clinical Trial Safety:

• 72 TBI patients: No serious adverse events reported
• 75 elderly subjects: Well-tolerated
• General Assessment: "Generally small side effect profile for peptide bioregulators"

Duration of Safety Data:

• Maximum documented: 30 days continuous use
• Long-term safety (>6 months) unknown

Reported Adverse Effects

Common (Mild, <10% estimated incidence):

• Headaches: Most frequently reported; usually mild and self-limiting
• Nausea: Transient GI discomfort
• Injection site reactions (SC route): Redness, swelling, pain at injection site
• Fatigue or lightheadedness: Occasional

Uncommon:

• Muscle aches
• Flushing
• Mild fever (rare)
• Allergic reactions: Skin rash, itching (very rare)

Serious Adverse Events:

• NONE documented in published literature
• Absence of SAEs may reflect limited sample sizes and short trial durations

Theoretical Safety Concerns

1. Cancer Risk (UNRESOLVED):

• Concern: Peptide bioregulators modulate gene expression; could theoretically promote cell proliferation in malignant cells
• Khavinson's Data: Claims bioregulators are "anti-cancer" via DNA repair enhancement
• Counterpoint: No long-term human cancer surveillance; prudent to avoid in active malignancy

2. Immunogenicity:

• Short peptides (3 amino acids) have low immunogenic potential
• Repeated administration unlikely to trigger anti-drug antibodies (ADAs)
• No hypersensitivity reactions reported

3. Hormonal / Neuroendocrine Effects:

• Pinealon derived from pineal gland; pineal regulates melatonin and circadian rhythms
• No evidence of altered melatonin levels or circadian disruption in trials
• Theoretical concern in individuals with circadian disorders

4. Drug-Drug Interactions:

• NO systematic interaction studies
• Theoretical interactions:
  • Anticoagulants: No known interaction; monitor INR if concerned
  • Psychotropic medications: May have additive cognitive effects (speculative)
  • Immunosuppressants: Unknown impact on immune function

Contraindications (Theoretical)

Absolute:

• Active brain tumor or history of CNS malignancy
• Known hypersensitivity to Pinealon or bioregulators

Relative:

• Pregnancy and lactation (no safety data)
• Children and adolescents (inappropriate use)
• Severe hepatic or renal impairment (altered PK)

Monitoring Recommendations

Baseline (If Attempting Use):

• Medical history and physical exam
• Cognitive baseline (MoCA, MMSE)
• Optional: Liver function (ALT, AST), renal function (creatinine)

During Treatment:

• Monitor for adverse effects (headaches, nausea)
• Cognitive re-assessment at 4 weeks

Long-Term (If Using >3 Months):

• Repeat labs every 6 months
• Annual age-appropriate cancer screening
• Report new neurological symptoms to physician

Adverse Event Reporting:

• Report suspected adverse reactions to FDA MedWatch (1-800-FDA-1088)

Regulatory & Legal Context

FDA Status:

• NOT FDA-approved for any indication
• Marketed as "research chemical" labeled "Not for Human Consumption"

Quality Concerns:

• No FDA oversight of manufacturing
• Third-party COAs (Certificates of Analysis) may not be reliable
• Risk of contamination, incorrect dosing, or counterfeit products

References:

• Pinealon Peptide Safety - Innerbody
• Pinealon Peptide Benefits & Side Effects - BC9

Storage & Stability

Lyophilized Powder:

• Store at -20°C to -80°C (freezer)
• Protect from light and moisture
• Shelf life: 24 months when properly stored

Reconstituted Solution:

• With Bacteriostatic Water: Refrigerate at 2-8°C; stable for up to 14 days
• With Sterile Water: Use within 72 hours
• Never refreeze reconstituted peptide

Degradation Factors:

• Temperature >25°C accelerates breakdown
• Moisture exposure (hygroscopic powder)
• pH extremes (<5.0 or >9.0)

Alternative Suppliers (Not Recommendations):

• Peptide Sciences: Pinealon 20 mg vials (~$150)
• Integrative Peptides: Pineal Bioregulator oral capsules
• Various international sources

Clinical Insights - Practitioner Dosing

Source: YouTube practitioner interviews

• s product have solutions in capsules dosed in the microgram range when the equivalent human dose is 8. 1 mg per kilogram two times per day.

Stacking Insights

• single peptide book published on Amazon only to find they were primitive cave drawings filled with incorrect science and dangerous misinformation.
• nformation. If you've seen our science check articles, you already know how other so-called experts stack up.

References & Citations

1. Pinealon - Wikipedia
2. EDR Peptide: Gene Expression in Alzheimer's - PMC7795577
3. Pinealon: Bioregulator Peptide - Peptide Sciences
4. Pinealon Research on Neuroprotection - Core Peptides
5. Pinealon Increases Cell Viability - ResearchGate
6. Pinealon Brain & Memory Support - Paragon
7. Pinealon Peptide Benefits - Innerbody
8. Pinealon Dosage Protocol - Peptide Dosages
9. Khavinson Peptide Bioregulators Guide
10. Overview of Pineal Tetrapeptides - PMC

Document Version: 1.0 Last Updated: December 2024 Classification: Experimental Neuroprotective Peptide